Last reviewed · How we verify

NCT02288299: LIAM

Long-Term Effect of LIAM on Respiratory Performance in NIV Patients Suffering From Neuromuscular Disease

Status unknown NA Last updated 18 November 2019
What this trial tests

NA trial testing non invasive mechanical ventilation in Neuromuscular Disease in 30 participants. Status unknown.

Timeline
29 October 2015
Primary endpoint
31 December 2021
31 December 2021

Quick facts

Lead sponsorCentre d'Investigation Clinique et Technologique 805
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment30
Start date29 October 2015
Primary completion31 December 2021
Estimated completion31 December 2021
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre d'Investigation Clinique et Technologique 805 — full company profile →

Who can join

18 and older, any sex, with Neuromuscular Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The long-term effect of LIAM (Lung Insufflation Assist Maneuver) on respiratory performance in home non-invasively ventilated (NIV) patients suffering from neuromuscular disease will be assessed in a prospective, randomized, cross over, open label study

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Neuromuscular Disease

Currently open trials in the same condition.

Other Centre d'Investigation Clinique et Technologique 805 trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02288299.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing